A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Study sponsor: Aura Biosciences
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-11-15Estimated
Enrollment · participants108Actual
Source updated2026-10-13Last update listed in the registry record